David Thorne

0 POSTS 0 COMMENTS
David Thorne is Chair, Washington Community Healthcare and Non-Executive Director, City and Vale GP Alliance.

Latest articles

public awareness in choice of hospitals

Lack of public awareness in choice of hospitals when accessing NHS treatment

A new poll by Populus has identified a lack of public awareness in choice of hospitals when accessing NHS treatment. Populus interviewed 6116 adults online...
Seqirus to make entire influenza vaccine production process cell-based

Seqirus to make entire influenza vaccine production process cell-based

Influenza vaccine manufacturer Seqirus is to manufacture its cell-based influenza vaccine (FLUCELVAX® TETRA) using cell-based Candidate Vaccine Viruses (CVVs) for all four strains recommended...
final recommendation for ILUMETRI ®▼

NICE publishes final recommendation for ILUMETRI ®▼

NICE has published final recommendation for ILUMETRI ®▼ (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis. The National Institute for Health and Care...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
positive recommendation for inotersen to treat adult patients with hATTR amyloidosis.

Tegsedi™▼ to be available on the NHS for hATTR amyloidosis

NICE issues positive recommendation for inotersen to treat adult patients with stage 1 or stage 2 polyneuropathy with hATTR amyloidosis.  Akcea Therapeutics UK Ltd., has...
final recommendation for ILUMETRI ®▼

NICE publishes final recommendation for ILUMETRI ®▼

NICE has published final recommendation for ILUMETRI ®▼ (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis. The National Institute for Health and Care...
Novartis apply for Priority Review of brolucizumab

Novartis announce FDA Priority Review of brolucizumab for wet AMD

Novartis has recieved FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD.  Novartis has announced that the US Food and...
Seqirus to make entire influenza vaccine production process cell-based

Seqirus to make entire influenza vaccine production process cell-based

Influenza vaccine manufacturer Seqirus is to manufacture its cell-based influenza vaccine (FLUCELVAX® TETRA) using cell-based Candidate Vaccine Viruses (CVVs) for all four strains recommended...